Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. Our diverse pipeline includes eteplirsen, our lead program for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. We aim to build a leading, independent biopharmaceutical company dedicated to translating RNA-based science into transformational therapies for patients who face significant unmet medical needs.
|View printer-friendly version|
|Sarepta Therapeutics Announces Pricing of $100.7 Million Public Offering of Common Stock|
BofA Merrill Lynch,
Sarepta intends to use the net proceeds from the offering for business development, manufacturing, the continued development of eteplirsen and other product candidates and other general corporate purposes.
The shares are being offered by Sarepta pursuant to an automatically
effective shelf registration statement that was previously filed with
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Sarepta, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements and Information
This press release contains statements that are forward-looking,
including the statements about the completion timing and size of the
proposed public offering of Sarepta’s common stock, the expected net
proceeds from the offering and Sarepta’s expected use of the net
proceeds from this offering, within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. These forward-looking statements involve risks and uncertainties
many of which are beyond Sarepta’s control including risk and
uncertainties related to market conditions and satisfaction of customary
closing conditions related to the proposed public offering. There can be
no assurance that Sarepta will be able to complete the public offering
on the anticipated terms or at all. Applicable risks also include those
that are included in the “Risk Factors” section of Sarepta’s Annual
Report on Form 10-K for the year ended
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward–looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings.